fda compounding semaglutide crackdown news today 2025 proposes a new GLP-1 FDA Update: Current Guidelines for

At the 12 mg dose: 28.3% average weight loss (about 70 lbs) 45.3% of patients lost 30% or more of their body weight 65.3% of patients dropped below a BMI of 30 Patients with baseline BMI 35 who stayed for 104 weeks lost 30.3% on average (85 lbs), with no plateau in sight Discontinuation due to side effects: 11.3% at 12 mg vs

Retinal disorders in people with type 2 diabetes

Where it comes from Most research-grade retatrutide is synthesized by peptide manufacturers in China

Slightly less interest in snacking between meals

Some research suggests tirzepatide users may experience fewer severe GI side effects than expected given its dual mechanism, but responses are highly individual

semaglutide, when each drug was compared to a placebo in separate clinical trials: Common side effects unique to liraglutide (Saxenda) include increased lipase and fever